We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Coca-Cola, Danaher, Medtronic, Goldman Sachs and Ford
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 31, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Coca-Cola Company (KO - Free Report) , Danaher Corporation (DHR - Free Report) , Medtronic plc (MDT - Free Report) , The Goldman Sachs Group, Inc. (GS - Free Report) and Ford Motor Company (F - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Coca Cola, Danaher and Medtronic
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Co., Danaher Corp. and Medtronic. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Coca-Cola have outperformed the Zacks Beverages - Soft drinks industry over the past year (+12.4% vs. +11.8%). The Zacks analyst believes that shares of Coca-Cola outpaced the industry in the past year, thanks to its robust earnings surprise trend that continued in second-quarter 2021. This marked the seventh straight quarter of earnings beats and its second consecutive sales beat.
The company's top line bounced back from the decline witnessed in the prior-year quarter, mainly owing to the increased consumer mobility and reopening of economies in several regions, which led to increased away-from-home channel sales. Revenues reflected gains from improved price/mix, an increase in concentrate sales and higher unit case volume.
The company is poised to gain from accelerating investments to expand its digital presence. However, the company witnessed pressures from higher supply chain costs, including transportation and commodity costs. It witnessed higher marketing spends compared with the prior-year quarter.
Danaher shares have gained +24.6% over the last three months, against the Zacks Diversified Operations industry's gain of +5.5%. The Zacks analyst believes that the company is poised to gain from Danaher Business System ("DBS"), the policy of rewarding shareholders through dividend payments, synergistic benefits from acquired assets (with 1% contribution to sales growth in second-quarter 2021) and investment in product innovation in the quarters ahead.
The company anticipates core revenue growth in the mid-to-high teens for the third quarter of 2021 and in the high teens for 2021. However, a rise in costs and expenses can be concerning for the company. In the past 60 days, its earnings estimates have been increased for the third quarter of 2021, 2021 and 2022.
Shares of Medtronic have outperformed the Zacks Medical - Products industry over the past three months (+5.7% vs. +1.5%). In fact, Medtronic's first-quarter fiscal 2022 earnings and revenues were ahead of the respective Zacks Consensus Estimate. Aside from Diabetes, every operating segment and geography registered strong year-over-year growth on an organic basis.
The Zacks analyst believes that the results reflected a strong recovery from the impact of the pandemic on elective procedures with most of Medtronic businesses finishing at or above pre-COVID levels. This reflected solid execution and continued procedure volume recovery. The quarter's gross and operating margins showed stupendous improvement on a year-over-year basis. The increase in the lower-end of Medtronic's fiscal 2022 EPS guidance buoys optimism.
On the flip side, the company's performance got dented by deferred procedures due to the emergence of Delta variant in several geographies including the United States.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Coca-Cola, Danaher, Medtronic, Goldman Sachs and Ford
For Immediate Release
Chicago, IL – August 31, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Coca-Cola Company (KO - Free Report) , Danaher Corporation (DHR - Free Report) , Medtronic plc (MDT - Free Report) , The Goldman Sachs Group, Inc. (GS - Free Report) and Ford Motor Company (F - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Coca Cola, Danaher and Medtronic
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Co., Danaher Corp. and Medtronic. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Coca-Cola have outperformed the Zacks Beverages - Soft drinks industry over the past year (+12.4% vs. +11.8%). The Zacks analyst believes that shares of Coca-Cola outpaced the industry in the past year, thanks to its robust earnings surprise trend that continued in second-quarter 2021. This marked the seventh straight quarter of earnings beats and its second consecutive sales beat.
The company's top line bounced back from the decline witnessed in the prior-year quarter, mainly owing to the increased consumer mobility and reopening of economies in several regions, which led to increased away-from-home channel sales. Revenues reflected gains from improved price/mix, an increase in concentrate sales and higher unit case volume.
The company is poised to gain from accelerating investments to expand its digital presence. However, the company witnessed pressures from higher supply chain costs, including transportation and commodity costs. It witnessed higher marketing spends compared with the prior-year quarter.
(You can read the full research report on Coca-Cola here >>>)
Danaher shares have gained +24.6% over the last three months, against the Zacks Diversified Operations industry's gain of +5.5%. The Zacks analyst believes that the company is poised to gain from Danaher Business System ("DBS"), the policy of rewarding shareholders through dividend payments, synergistic benefits from acquired assets (with 1% contribution to sales growth in second-quarter 2021) and investment in product innovation in the quarters ahead.
The company anticipates core revenue growth in the mid-to-high teens for the third quarter of 2021 and in the high teens for 2021. However, a rise in costs and expenses can be concerning for the company. In the past 60 days, its earnings estimates have been increased for the third quarter of 2021, 2021 and 2022.
(You can read the full research report on Danaher here >>>)
Shares of Medtronic have outperformed the Zacks Medical - Products industry over the past three months (+5.7% vs. +1.5%). In fact, Medtronic's first-quarter fiscal 2022 earnings and revenues were ahead of the respective Zacks Consensus Estimate. Aside from Diabetes, every operating segment and geography registered strong year-over-year growth on an organic basis.
The Zacks analyst believes that the results reflected a strong recovery from the impact of the pandemic on elective procedures with most of Medtronic businesses finishing at or above pre-COVID levels. This reflected solid execution and continued procedure volume recovery. The quarter's gross and operating margins showed stupendous improvement on a year-over-year basis. The increase in the lower-end of Medtronic's fiscal 2022 EPS guidance buoys optimism.
On the flip side, the company's performance got dented by deferred procedures due to the emergence of Delta variant in several geographies including the United States.
(You can read the full research report on Medtronic here >>>)
Other noteworthy reports we are featuring today include The Goldman Sachs Group and Ford Motor.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.